Core Scientific (CORZ) Draws Bullish Valuation Calls, Is The Stock Still A Bargain?
Executive appointment puts Core Scientific’s commercial strategy in focus
Core Scientific (CORZ) drew fresh attention after the company expanded its leadership bench, naming industry veteran Jay Elms as Chief Commercial Officer with responsibilities spanning customer relationships and end to end deployment.
The announcement comes as investors reassess how the miner and colocation provider is valued in relation to its contracted capacity and long term earnings potential highlighted in recent research coverage.
Recent trading has been choppy for Core Scientific, with the share price ending at US$15.94 after declining 10.9% over the past month and 32.9% over the past quarter, while the 1 year total shareholder return is down 9.1%. This points to fading momentum even as upbeat research coverage and this C-suite hire refocus attention on how the market is treating the company’s contracted capacity and earnings outlook.
Compare Core Scientific’s setup with hand picked peers by scanning 92 AI infrastructure stocks positioned to benefit from demand for high density computing capacity and digital asset infrastructure.
Bulls point to fresh leadership and analyst enthusiasm around Core Scientific’s contracted capacity, while bears focus on recent share price declines and current losses. Which side do the numbers lean toward as you weigh valuation next?
Most Popular Narrative: 53% Undervalued
Core Scientific’s most followed valuation narrative puts fair value at $33.90, well above the last close at $15.94. This frames the new commercial hire within a story built on aggressive growth and improved profitability assumptions.
The analysts have a consensus price target of $33.9 for Core Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $55.0, and the most bearish reporting a price target of just $16.0.
See why 61 investors see Core Scientific as 53% undervalued.
Result: Fair Value of $33.90 (UNDERVALUED)
Still, if Core Scientific’s high performance computing buildout slips, or its heavy reliance on CoreWeave weakens, the bullish valuation narrative could quickly unravel.
Find out about the key risks to this Core Scientific narrative.
Another View: Core Scientific’s Price Tag Looks Full
That 53% analyst upside for Core Scientific meets a very different message from the market. On sales, the stock trades on a P/S of 11.6x, while the US Software industry sits near 3.9x and peers are closer to 3.7x. The fair ratio estimate of 5.8x suggests investors are already paying up heavily for the story. If profit is still some way off, how comfortable are you owning a business where sentiment, not earnings, seems to carry most of the weight?
Before leaning too hard on any one narrative, it may help to see how these pricing gaps fit into a fuller breakdown of the numbers, risks, and assumptions that drive that P/S premium See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages on Core Scientific can feel like noise, so move quickly, review the underlying data, and weigh both the upside and the warning flags through 1 key reward and 3 important warning signs
Looking for more Core Scientific sized ideas?
If Core Scientific has you thinking harder about risk, reward, and timing, do not stop here. Use the screener to spot opportunities before everyone else.
- Target potential mispricings by scanning 29 high quality undervalued stocks that combine strong fundamentals with what may be overly cautious market expectations.
- Prioritise resilience first and hunt through 31 resilient stocks with low risk scores where balance sheets and risk scores work harder to protect your downside.
- Hunt for future leaders early by checking the 20 high quality undiscovered gems that pair quality metrics with limited current market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com